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and Management
A Scientific Statement From the American Heart Association
Nancy A. Rudd, MS, CPNP-PC/AC, Chair; Nancy S. Ghanayem, MD, MS; Garick D. Hill, MD;
Linda M. Lambert, MSN, CFNP; Kathleen A. Mussatto, PhD, RN; Jo Ann Nieves, MSN, PNP-BC;
Sarah Robinson, MSM; Girish Shirali, MBBS; Michelle M. Steltzer, MS, CPNP-PC/AC; Karen Uzark, PhD, CPNP;
Nancy A. Pike, PhD, CPNP-PC/AC, Vice Chair; on behalf of the American Heart Association Council on
Cardiovascular and Stroke Nursing; Council on Lifelong Congenital Heart Disease and Heart Health in the
Young; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology;
and Council on Lifestyle and Cardiometabolic Health

Downloaded from http://ahajournals.org by on June 24, 2021

ABSTRACT: This scientific statement summarizes the current state of knowledge related to interstage home monitoring for
infants with shunt-dependent single ventricle heart disease. Historically, the interstage period has been defined as the time of
discharge from the initial palliative procedure to the time of second stage palliation. High mortality rates during the interstage
period led to the implementation of in-home surveillance strategies to detect physiologic changes that may precede hemodynamic decompensation in interstage infants with single ventricle heart disease. Adoption of interstage home monitoring
practices has been associated with significantly improved morbidity and mortality. This statement will review in-hospital readiness for discharge, caregiver support and education, healthcare teams and resources, surveillance strategies and practices,
national quality improvement efforts, interstage outcomes, and future areas for research. The statement is directed toward
pediatric cardiologists, primary care providers, subspecialists, advanced practice providers, nurses, and those caring for
infants undergoing staged surgical palliation for single ventricle heart disease.
Key Words: AHA Scientific Statements ■ cardiovascular abnormalities ■ caregivers ■ infant ■ univentricular heart
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n the recent era of congenital heart disease management, no defect has undergone more dramatic
improvement in outcomes than hypoplastic left
heart syndrome (HLHS) and related variants that require staged palliation for single ventricle heart disease
(SVHD) with aortic hypoplasia. Stage 1 palliation (S1P)
includes the surgical Norwood procedure or the hybrid alternative. The Norwood procedure consists of
atrial septectomy, Damus-Kaye Stansel connection of
pulmonary and aortic roots, aortic arch reconstruction, ligation of the ductus arteriosus, and placement
of a modified Blalock-Taussig shunt or right ventricle
to pulmonary artery shunt. The hybrid procedure includes stenting of the ductus arteriosus, pulmonary
artery banding, and balloon atrial septostomy. Also
included in the group of shunt-dependent SVHD patients are single ventricle lesions that require surgical
systemic-to-pulmonary shunt placement or stenting
of the ductus arteriosus. Advancements in care span
operative, postoperative, and interstage management.
Before 2000, the postdischarge care provided after
Norwood S1P, lacked the level of surveillance needed
to manage this high-risk population. Due to published
mortality rates as high as 16% between discharge after
S1P and stage 2 palliation (S2P), Ghanayem and colleagues (2003) developed an innovative home monitoring strategy.1,2 The foundations of interstage home
monitoring (IHM) are routine caregiver home surveillance of oxygen saturations, enteral intake, and weight
change during the interstage period; early healthcare
team notification of any abnormal parameters labeled
as “red flags”; or other changes in clinical condition.
This heightened in-home surveillance augments conventional outpatient management to detect physiologic
changes that may precede hemodynamic decompensation in high-risk infants with shunt-dependent SVHD.
IHM programs, using family and healthcare provider
engagement, have led to improved survival to S2P for
infants who have undergone either Norwood procedure or hybrid procedure S1P, for HLHS and related
variants.3–5
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saturation. Sao2 depends on the balance between systemic and pulmonary flow, lung health, and systemic
venous saturation. The most life-threatening risk associated with shunt-dependent SVHD, particularly with
a modified Blalock-Taussig shunt or ductus arteriosus
stent, is an abrupt reduction in pulmonary blood flow,
thus highlighting the importance of monitoring Sao2
trend during the interstage period. A more gradual
reduction in pulmonary blood flow or pulmonary venous desaturation will also lead to a fall in Sao2. This
reduction in Sao2 is dependent on an ability to increase
systemic blood flow to maintain tissue oxygen delivery.
Inability to augment systemic blood flow will result in
lower systemic venous saturation and further reduce
Sao2. The inefficiency of parallel circulation combined
with cyanosis, limited myocardial reserve, and autonomic responses to stress, places the infant with
shunt-dependent circulation at risk for critical impairment of oxygen delivery.
Multiple cardiac and noncardiac causes have
been implicated in interstage death. Most common
are residual or recurrent lesions and development of
intercurrent childhood illness. Restrictive atrial communication, arch obstruction, obstructed shunt flow,
pulmonary artery distortion, atrioventricular valve insufficiency, and arrhythmias have each been associated with interstage mortality (Figure 1).1,4,6,7 Of the

SHUNT-DEPENDENT PHYSIOLOGY
AND ASSOCIATED INTERSTAGE RISK
FACTORS
The physiologic challenge associated with shunt-dependent single ventricle, also referred to as functionally univentricular heart disease, is the persistence of
parallel circulation that extends beyond the surgical
hospitalization to shunt takedown at S2P. Inherent to
parallel circulation are critical relationships between
oxygen consumption, pulmonary blood flow, systemic
blood flow, partially oxygenated arterial blood (Sao2),
systemic venous saturation, and pulmonary venous

Figure 1. Pathophysiology associated with changes in
oxygen saturation for shunt-dependent single ventricle
heart defects.
The figure illustrates differential diagnoses to consider when
oxygen saturation thresholds are breached after Norwood
palliation with a modified Blalock-Taussig shunt for hypoplastic
left heart syndrome. Similar pathophysiologic considerations are
applicable to the right ventricle to pulmonary artery shunt, hybrid
palliation, and other shunt-dependent single ventricle variants.
Used with permission from Texas Children’s Hospital. Copyright
© 2019 Texas Children’s Hospital.
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≈2000 infants with shunt-dependent SVHD enrolled in
the National Pediatric Cardiology Quality Improvement
Collaborative (NPC-QIC) Phase 1 registry, 17% had
at least 1 unplanned interstage intervention with the
majority being catheter-based. The most common
surgical reintervention was modified Blalock-Taussig
shunt revision or placement, and the most common
catheter intervention was on the aortic arch.6 The
Congenital Heart Surgeons’ Society identified a 25%
incidence of arch reintervention at a median age of
4.3 months in those who had Norwood palliation.7
Single center reports and the multicenter Pediatric
Heart Network Single Ventricle Reconstruction trial
report a higher incidence of interstage mortality in infants who underwent modified Blalock-Taussig shunt
compared with the right ventricle-to-pulmonary artery
shunt.8 Whether the mechanism of increased mortality with the modified Blalock-Taussig shunt is predominantly because of impairment of coronary perfusion
or shunt obstruction remains unknown. Noncardiac
causes such as poor feeding and acquired childhood
gastrointestinal or respiratory illnesses that result
in hypovolemia or acute hypoxemia have also been
implicated as causes for interstage death.9,10 Any of
the aforementioned processes may critically influence
systemic vascular resistance, increase metabolic demands, and potentiate progressive hypoxia or shock,
either hypovolemia or cardiogenic, in the infant with
S1P physiology.

INTERSTAGE HOME MONITORING
METRICS AND RED FLAGS
IHM was initially implemented for the purpose of reducing mortality, and this continues to be the most
reported metric.3,10–12 In-home use of pulse oximetry to detect excessive hypoxia and infant scales to
detect weight loss remain standards of monitoring.
Tracking weight can identify dehydration as well as
somatic growth failure which has been modifiable.12,13
Additional interstage metrics include heart rate trends,
adequate oral intake (≥100 mL/kg per day), and occurrence of major events with serious, or even fatal,
consequences (eg, cardiac arrest, arrhythmias, sepsis,
or thrombotic events).
Healthcare team consensus determined physiologic parameters to be monitored, and concerning
changes in those parameters are denoted as “red
flags” (Table 1). Any breach of these criteria detected by
caregivers should trigger notification of the healthcare
team. These parameters may vary somewhat based
on infant-specific physiology or program-specific management but commonly caregivers are instructed to
notify the healthcare team if any red flags or other unusual symptoms arise.

Interstage Home Monitoring for Infants

Table 1. Common Interstage Home Monitoring Red
Flags 4,10,14,15
Red Flags
Oxygen saturation ≤75%*
Failure to gain 20 g (=0.02 kg) in 3 d
Weight loss ≥30 g (=0.03 kg)
Enteral intake <100 mL/kg per d
Cyanosis, pallor
Irritable, fussy
Diarrhea or vomiting
Increased sweating
Respiratory changes (tachypnea, distress)
Temp >100.4°F
*Unanticipated increase in oxygen saturation from baseline (eg ≥90% in
infant with Norwood physiology) should be considered a red flag.

INPATIENT PREPARATION FOR
INTERSTAGE HOME MONITORING
Medical Readiness for Discharge
Criteria for discharge to IHM vary by institution and
some infants may not be candidates for home management. At a minimum, infants should demonstrate
cardiac stability with acceptable oxygen saturations,
adequate weight gain on a stable feeding regimen,
and no inpatient breach of red flag criteria for monitored metrics. Before discharge echocardiography
should be completed to assess for known risk factors
for adverse outcomes such as tricuspid regurgitation
and ventricular dysfunction,1 as well as residual lesions
such as aortic coarctation, atrial septal restriction,
and shunt or branch pulmonary artery stenosis.16,17
Knowledge of the infant’s hospital course is also critical to determine readiness for discharge. A history of
genetic abnormality or preterm gestation, extracardiac
abnormalities, arrhythmias, prolonged dependence
on inotropic support, and the need for extracorporeal
membrane oxygenation, have all been associated with
adverse outcomes following S1P.4,9,10,16 Thus, selective
inpatient interstage management has been proposed
and is a strategy used at some centers for infants considered high risk.18

Home Equipment
In preparation for discharge caregivers are taught the
necessary skills to care for and monitor their infant at
home.19,20 Essential IHM equipment includes a portable pulse oximeter with infant-appropriate probes
and a digital infant scale sensitive to weight changes
of ≤10 g.21 Assistance with obtaining equipment and
other home supplies or services can be provided by a
case manager. In some regions, the cost of pulse oximeters and scales may be covered by insurance and
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provided by suppliers of durable medical equipment.
Occasionally a letter of medical necessity stating the
high risk of morbidity and mortality is needed. At some
centers equipment or tablet-based devices are purchased using charitable donations or by the institution
and loaned to families for the duration of the interstage
period. Provision of equipment and resources needed
to support IHM may prove challenging and cost prohibitive at any given center.

Caregiver Education
Caregivers require training in equipment use, daily
measurements, recording (eg, binder with paper logs,
home telemedicine system, cellular phone application),
and interpreting data (eg, oxygen saturation, heart
rate, weight, nutritional intake) based on infant–specific
parameters and previous trends.10,14,22–25 Beginning
this education early in the inpatient stay allows time
for caregivers to become competent and confident in
their ability to perform IHM tasks. They must learn to

accurately calculate daily nutritional intake and weight
changes.4,10,12,24 Depending on the recording application used, selected programs can electronically
calculate these changes, follow trends and provide
automatic red flag notifications.22–24 In addition, medical knowledge of their infant’s condition, medication
administration, general infant care, preparation of calorically enhanced formula, feeding administration (eg,
oral, nasogastric, or gastrostomy tube), schedules for
follow-up appointments, and IHM team contacts must
be provided in writing (Table 2).14,25,26
Care demands and other family stressors, may
impair or delay caregiver learning and possibly delay
discharge.19,26,27,29 The healthcare team should allow
adequate time for training and monitor for any indications that the caregivers may require additional
support or retraining. Training >1 caregiver is preferable and allows support and respite for the primary
caregiver. Caregivers should repeatedly practice
these skills before discharge and be able to verbalize

Table 2. Discharge Preparation and Education Checklist14,15,27,28
Topic

Content

Resources/Evaluation Method
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Individualized cardiac defect*

[]R
 eview diagram of cardiac defect, surgical
interventions, oxygen saturations, and future surgeries

[ ] Written material/diagrams
[ ] Peer-reviewed web links for CHD information

IHM equipment and plan of
care*

[]E
 xplain IHM program purpose, goals, and
participation requirements
[ ] Review IHM team members and contact information
[]R
 eview equipment use (eg, scales, pulse oximeter,
oxygen—if needed)
[]R
 eview clinical data entry system (eg, paper or webbased with technical support)
[ ] Red flag list and action plan
[ ] Emergency department plan

[]W
 ritten material and demonstration of equipment use
with teach back
[]R
 ecording saturation, heart rate, weight change, and
intake volume total
[ ] Verbalize red flags
[]S
 tore a copy of the emergency action plan in IHM
binder and/or cellular phone

General postoperative care*

[ ] Medication list and schedule
[ ] Written nutrition plan
[ ] Enteral feeding supplies
[ ] Activity/sternal precautions
[ ] Incisional care
[ ] Infection prevention
[ ] Immunization plan (include Synagis)
[ ] Infectious endocarditis prophylaxis
[ ] Infant CPR training
[]G
 eneral newborn care (eg, bathing, cord care,
temperature, normal development, car seat test)

[ ] Written material on content listed and other infant care
[]D
 emonstration of preparing correct dosing of
medication
[]P
 reparation of calorically enhanced breast milk or
formula
[ ] Demonstrate feeding tube care and pump use
[]D
 emonstrate normal infant care and verbalize when to
call the provider

Scheduled appointments*
(goal of infant seeing a
provider within 72 h of
discharge)

[ ] Primary care provider
[ ] Pediatric cardiologist
[ ] IHM clinic
[]O
 ther subspecialist (eg, genetics, GI, ENT, general
surgery, neurology)
[ ] Cardiac neurodevelopmental clinic

[]W
 ritten material with contact Information for all
providers/clinics telephone numbers
[ ] IHM contact information on emergency card and stored
in IHM binder or cellular phone

Discharge Materials*

[]C
 aregiver keeps a copy of discharge instructions,
medication list, hospital discharge summary in
accessible locations such as diaper bag, IHM binder,
or cellular phone

[ ] Written material (copy of discharge summary)

Support group information*

[]P
 rovide local, and national CHD support group
websites

[ ] Written material with downloadable links

Competency in care

[]C
 aregiver rooms in for 24 h (minimum) to demonstrate
independent care before discharge

[]N
 ursing staff and IHM team determination of safe and
competent care

CHD indicates congenital heart disease; CPR, cardiopulmonary resuscitation; ENT, ears, nose, and throat; GI, gastrointestinal; and IHM, interstage home
monitoring.
*Provide information in family/caregiver’s native language.
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a stepwise process for action should a red flag or
concerning symptom be identified that requires reporting. A “rooming in” period for 24 to 48 hours in
the hospital is often encouraged to assess the caregiver’s ability to independently perform all aspects of
care.15 This experience allows caregivers to imitate
a home environment with the healthcare team available for support and can ease the transition to home.
Various institutional-specific educational forms or
tools have been developed to assist families with
identifying red flags and infant-specific parameters
and have been translated into multiple languages.15,27
NPC-QIC has also developed comprehensive standardized clinical care processes, resources, and
tools for IHM education.28,30

Coordination With Healthcare Providers
Well-coordinated, comprehensive communication of
the hospitalization, surgical palliation, and IHM plan
of care between all healthcare providers is vital for
effective management of the highly complex, fragile infant in the outpatient setting.10,14,17,25,30 Building
a close, multidisciplinary collaboration between the
caregivers, the IHM team, and healthcare providers
in the medical home is advantageous in facilitating a
supportive network for the IHM period.19,25 In addition to sharing a written discharge plan of care17 with

all healthcare providers, the NPC-QIC recommends
IHM programs incorporate a predischarge team conference call to communicate and coordinate an effective care transition (Table 3). Call participants should
include the caregivers, outpatient primary care providers, and local pediatric cardiologists, along with
the inpatient healthcare team to allow for review of
the plan of care and to establish open communication.30 Close communication between the IHM team
and local cardiologists and primary care providers
can foster timely evaluation and management of
medical concerns.

INTERSTAGE MEDICAL HOME
A collaborative, specialized multidisciplinary team
to provide coordinated interstage management has
been successfully and widely adopted at multiple
centers.4,10,21,23,31 The IHM team typically consists
of pediatric cardiologists, nurses, advanced practice providers, dieticians, occupational and physical therapists, and/or speech-language pathologists
knowledgeable in inpatient and outpatient management of infants with shunt-dependent SVHD. The
concept for the interstage medical home is consistent with the US Department of Health and Human
Services Healthy People 2010 and 2020 goals and
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Table 3. Discharge Communication to Healthcare Providers Checklist15,28
Communication Topics

Content

Review diagnosis, interventions or procedures, and
postoperative course

[ ] Provide copy of discharge summary
[ ] Review diagnosis, surgical intervention and shunt site, residual defects or concerns, baseline
vital signs, oxygen saturation and weight, and any extracardiac anomalies (eg, genetic
syndrome, neurologic issues, heterotaxy, asplenia, and dysphasia)

IHM team and management plan

[ ] Introduce IHM, team members, and 24-h access
[ ] Identify best contact numbers for pediatrician and IHM team to communicate during the
interstage
[ ] Discuss what will be monitored, goal parameters, review “red flag symptoms” and
communication needs across all specialties during the interstage period
[ ] Discuss the nutrition and medication plan, growth parameter goals, who will provide weekly
growth and nutrition evaluation with feeding plan advancements
[ ] Discuss any social concerns or barriers to access care

Appointments

[ ] Primary cardiologist
[ ] Primary care provider
[ ] Interstage clinic
[ ] Specialty medical clinics (eg, general surgery, genetics, neurology)
[ ] Therapies (physical, speech, and occupational)
[ ] Neurodevelopmental clinic follow-up (referral to local early intervention programs)
[ ] Cardiac catheterization date (if known)
[ ] Monthly palvizumab (RSV season only)
[ ] Any follow-up outpatient diagnostic or laboratory tests

Emergency plan

[ ] Identify the closest, equipped emergency department with guidelines on oxygenation and
hydration, and urgent contact with IHM team and primary cardiologists

Caregiver/family resources and support groups

[ ] Social worker, psychologist/mental health, discharge planner, or case manager contact
number
[ ] Local and national family support groups

Share documents

[ ] Center specific forms—Medical identification tools, wallet identification cards, red flag action
plans, interstage visit appointment summary, or NPC-QIC templates

IHM indicates interstage home monitoring; NPC-QIC, National Pediatric Cardiology Quality Improvement Collaborative; and RSV, respiratory syncytial virus.

J Am Heart Assoc. 2020;9:e014548. DOI: 10.1161/JAHA.119.0145485

Rudd et al

objectives for all children with special medical needs
to have access and receive ongoing, comprehensive
care.32 Establishing a medical home can optimize
the use of medical resources, expand the competence of involved providers, increase caregiver satisfaction, and improve interstage outcomes.10 An
important aspect of this medical home is neurodevelopmental surveillance through specialized cardiac
neurodevelopmental clinics and state-provided early
intervention services for high risk infants. Medical
home surveillance is advocated by national organizations (eg, NPC-QIC, American Heart Association,
American Academy of Pediatrics, and Cardiac
Neurodevelopment Outcome Collaborative) to reduce potential developmental delays associated with
chronic congenital cardiac conditions.33,34

CAREGIVER SUPPORT: TRANSITION
FROM HOSPITAL TO HOME

Downloaded from http://ahajournals.org by on June 24, 2021

Thoughtful preparation can make the transition from
hospital to home less stressful. Caregivers have
shown higher confidence and knowledge after discharge when actively participating in the care of their
infant while in the hospital.26 Despite this increased
competence, many caregivers still feel anxious with
the transition from inpatient to home.35 Stress, anxiety, and depression may increase when barriers to
education are present and resources are low. These
may include language barriers, low literacy, cultural
barriers, single or teenage caregivers, lack of family or
financial support, limited access to transportation, or
lack of insurance. Socioeconomic factors have been
shown to be associated with early mortality after
S1P.36 The IHM team can lessen these factors through
anticipating home needs and validating with caregivers stable trends in the infant’s monitored parameters
before discharge. An early postdischarge follow-up
phone call by the IHM team and home nursing visits
can provide additional valuable support to caregivers.
The high-risk nature of the interstage period and
rigorous daily care requirements not only affects the
caregivers but the entire family system, including siblings.27,37,38 Whether a first-time or experienced caregiver, interstage management is complex and beyond
the typical care of an infant without congenital heart
disease. Caregivers have expressed feelings of social
isolation and relied on close family and friends for support during this period.19 Thus, caregiver support must
continue after discharge with 24-hour access to the
IHM team and the ability to communicate with the IHM
team in their primary language. Caregivers need support and training to become an active member of the
medical team. A parent perspective on interstage home
monitoring is provided in the supplemental materials

Interstage Home Monitoring for Infants

available with this article. This includes the capability
to assess for red flags, report breaches to the healthcare team, share any parental concern and access the
emergency department or primary care setting to ensure care is provided without delay. The transition to
home is a pivotal step in fulfilling the caregiver’s goal
of “becoming a family,” which has been reported as an
important coping strategy during this time.19

NUTRITIONAL MANAGEMENT
Risk factors for growth failure during the interstage
period include inadequate caloric intake, increased
metabolic demands of heart failure, gastrointestinal dysfunction, or noncardiac comorbidities. Poor
feeding and decreased weight gain can be signs of
hemodynamic instability after S1P and have been associated with more complex postoperative course
at S2P.11,39 Regular assessment of caloric intake and
weight gain is needed throughout the interstage period to allow early identification of feeding difficulties
or inadequate growth. NPC-QIC efforts identified processes common to centers with positive interstage
weight gain and adoption of these strategies is vital
during IHM28,30 (Table 4). Targeted weight gain during
the interstage period is 20 to 30 g per day and often
requires enteral intake goals of 120 to 140 mL/kg per
day and 120 to 150 kcal/kg per day.40 Infant formula or
expressed breast milk often requires concentration to
22 to 30 calories/oz.40 Feeding routes used after S1P
include oral, tube, or a combination of these, including breastfeeding, if the infant’s clinical condition allows. Each infant’s home nutrition plan should include
type and route of enteral support needed to promote
growth and neurodevelopment.

ADDITIONAL INTERSTAGE
SURVEILLANCE STRATEGIES
Interstage surveillance strategies have evolved over the
past decade.10,29 Center variations occur based on staff,
resources, and access or distance to a cardiac center.
Table 4.

Nutrition Bundle*

Standard post-S1P feeding evaluation (eg, clinical, endoscopic, or
swallow evaluation
Home scale for interstage weight monitoring
Specific weight gain/loss “red flags” to identify patients with growth
failure in the interstage
Regular telephone contact with families during the interstage about
nutrition and growth
Dietitian available for each cardiology outpatient visit during the
interstage
*Modified from the National Pediatric Cardiology Quality Improvement
Collaborative (http://npcqic.org) Nutrition Bundle.28,30
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Despite center differences in surveillance, common
strategies include weekly communication with families,
interstage specialty clinics, and telehealth modalities.
Weekly communication between caregivers and the
IHM team provides an opportunity to review physiologic
and growth trends, update feeding plans, validate caregiver observations, provide anticipatory guidance, and
addresses any concerns. Algorithms to facilitate direct
and frequent communication between the caregiver
and IHM care team, referring cardiologist, and pediatrician have been developed by some centers.25,41,42
Interstage specialty clinics have evolved to meet
the multidisciplinary needs of infants after S1P, and
care is often provided by cardiology nurse practitioners, cardiologists, dieticians, and social workers.
Interstage clinic visits vary depending on distance
from center and type of monitoring (eg, telehealth).
Clinic visits afford the IHM team an opportunity to
validate weight trends and oxygen saturations using
clinic equipment, review data trends recorded by
caregivers, confirm medication dosages, review red
flags and how to reach IHM team, observe enteral
feeding, perform a comprehensive physical assessment, obtain diagnostic imaging if warranted, and
assess the emotional and social state of caregivers.
Other services that may be provided include speech,
occupational, and physical therapy to assess and
address developmental needs.
Currently, telehealth platforms are being used at
some centers for interstage surveillance through telephone or tablet-based applications including some
with real-time image and video transfer capabilities.
The proliferation of consumer-grade mobile devices
and secure, cloud-based services has laid the foundation for automated real-time analytics and notifications
to the healthcare team.22,43 Programs that integrate
IHM with clearly defined, automatic thresholds for notification of the healthcare team have demonstrated
improvements in survival, weight gain, and shorter interstage intensive care unit length of stay.22,43 These
technologies may help address socioeconomic disparities in interstage survival and potentially alleviate
some parental stress.22,35,43 Systematic analysis of
daily videos of the infant may provide important insights. Mobile technologies offer an ever-evolving
continuum of IHM and care in the outpatient setting.
However, consideration of the caregiver’s comfort
level with digital technology, access to wireless connectivity, and potential preference for traditional IHM
strategies should be acknowledged.

PROGRESSION TO STAGE 2
PALLIATION
Timing of elective S2P is variable but is typically performed between 3 and 6 months after S1P.44,45 One of

Interstage Home Monitoring for Infants

the effects of IHM has been a progression to earlier S2P
to mitigate risk in those infants with multiple breaches
of red flag criteria or those who fail to progress.46 Early
S2P may be more feasible as interstage weight gain
has improved in the era of IHM.9 Outcomes of S2P,
even when done at an early age, are comparable to
S2P done at standard age.47 A decision algorithm for
progression to S2P based on clinical markers is shown
in Figure 2.

TRANSITION ON COMPLETION OF
INTERSTAGE HOME MONITORING
The completion of IHM marks a major care transition
for caregivers and usually occurs after the completion
of S2P or a cardiac procedure (surgical or catheterbased) deemed to reduce an infant’s risk of acute decompensation at home. Caregivers have expressed
great relief around normalizing family routines and the
ability to focus on the infant’s developmental progress
once discharged after S2P.19 However, others shared
feelings of stress, anxiety and a heightened sense of
vigilance about caring for their infant without the aid of
home monitoring and frequent contact with the healthcare team.20 The healthcare team should be sensitive

Figure 2. Decision Algorithm for Progression to Stage 2
Palliation.
IHM indicates interstage home monitoring; S1P, stage 1 palliation;
and S2P, stage 2 palliation.
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to caregiver needs and priorities when preparing for
IHM completion. Assurance of ongoing support during
the transition of cardiac care from the IHM team to potentially new cardiology providers or location is critical
along with reinforcing the caregiver’s ability to assess
their infant without the use of monitoring equipment.
The completion of IHM should be viewed in a positive
light and caregivers should be praised for reaching the
S2P milestone.

EXPANSION OF IHM TO OTHER HIGHRISK INFANTS WITH CONGENITAL
HEART DISEASE
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Hypoplastic left heart syndrome is considered to
be among the highest risk of early mortality, even
after successful S1P and early IHM programs focused primarily on infants who had undergone S1P.2
More recently, single center reports have identified
non-HLHS single ventricle defects to also be at high
risk for interstage mortality (eg, heterotaxy anatomic
substrates, pulmonary atresia with intact ventricular
septum, or other defects with shunt-dependent pulmonary blood flow, and balanced circulation) supporting the expansion of IHM to all types of SVHD
both with and without a systemic-to-pulmonary
shunt.14,31,48 The potential to include biventricular
shunt-dependent defects that require an initial palliative procedure could be another area of inclusion.
Surgical practices such as primary transplant for
high-risk lesions or neonatal complete repair of previously palliated Congenital Heart Disease and center
resources may limit this expansion of IHM to additional lesions.

MULTICENTER INTERSTAGE QUALITY
IMPROVEMENT EFFORTS
The NPC-QIC was established in 2008 to improve
outcomes of HLHS during the interstage period
with an emphasis on reducing mortality and improving quality of life.49 Initial NPC-QIC publications
reported significant practice variation with regards
to care during the interstage period.17,41,50 In a comparison of data from 2 eras, there were significant
changes in infant-specific risk factors, surgical strategy, discharge communication, and interstage care
as measured by discharge processes, nutrition support, interstage monitoring, and surgical timing of
S2P.51 The work of this multicenter quality improvement collaborative resulted in improved knowledge
about best practices to manage interstage infants
and led to the development of an Interstage Change
Package, a resource containing multiple interstage
improvement strategies.28 NPC-QIC’s Phase 1
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efforts led to a decrease in interstage mortality by
>40% (9.5%–5.5%) and a decrease in growth failure
by 28% (18.6%–13.1%).30

INTERSTAGE HOME MONITORING
OUTCOMES
Improved Survival
Data from single centers with IHM programs report
success in reducing interstage mortality to as low as
2%.1,10,14,25,42,46,52 The NPC-QIC reported a decrease
in interstage mortality by >40% between 2008 and
2016.30 Although multiple factors likely contributed to
the decline, the widespread adoption of IHM strategies
at >50 cardiac centers participating in the collaborative
was thought to be the most impactful. Other variations
in practice and programmatic changes such as earlier
catheterization and S2P or hospitalization of high-risk
infants throughout the interstage period or following a
readmission may have also contributed to differences
in survival outcomes.30

Decreased Major Event Readmissions
Decreased readmissions for major events such
as cardiac arrest, shunt thrombosis, arrhythmias,
systemic infections, aspiration, stroke, or seizures
was a desired outcome of IHM.42 In contrast, readmissions prompted by red flags or concerning
symptoms were anticipated to increase as they
were considered important in allowing for prompt
assessment and prevention of major events. A recent study found infants with IHM were more likely
to be admitted than historical controls.42 Although
the IHM group had more readmissions, the duration
was shorter compared with controls with the majority being observational and requiring minimal or
no interventions. Analysis of the NPC-QIC registry
data revealed unanticipated interstage readmissions occurred in 66% of 815 infants at 50 centers.53
The median readmission length of stay was 2 days.
Most readmissions were prompted by minor clinical changes (eg, red flags). Only 6% were major adverse event readmissions. Given the lack of previous
data, it is difficult to determine whether IHM itself
has increased or decreased the frequency and type
of readmissions. However, it seems likely that early
readmissions based on red flag events identified by
IHM may prevent major adverse events.53 In support
of this scenario, 1 study noted the percentage of
IHM infants in their cohort requiring major interventions such as emergent surgery or an unscheduled
interventional catheterization, was similar to their
previously reported interstage mortality rates indicating these interventions may possibly represent
“near-miss deaths.”25
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Improved Growth
Although it was widely believed the complex medical problems of infants with HLHS would not allow
normal weight gain, an unexpected but welcomed
outcome of IHM was improved weight gain during the interstage period. 3 NPC-QIC data demonstrated use of a nutrition bundle (Table 4) and
home monitoring of weight was associated with
a 28% reduction in interstage growth failure. 30
Further analyses revealed that with appropriate
caloric goals and IHM, adequate growth could be
achieved regardless of feeding modality.18 Others
have reported improved interstage weight gain 31
and normal interstage growth velocity of 26 g/d
during the period associated with IHM.9 Frequent
weight monitoring provides more opportunities
for clinicians to detect growth failure early and
intervene to optimize the nutritional plan of care.
Interstage growth failure has been linked to a more
complex postoperative course and longer hospital
length of stay at the time of S2P. 39,49,54 Furthermore,
early growth failure in complex congenital heart
disease is associated with worse early developmental outcomes.55,56

GAPS IN KNOWLEDGE AND GOALS
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The major research gap associated with IHM is the
lack of a randomized controlled trial to assess the
role it plays in improvement in interstage mortality
and morbidity. IHM may be only one component,
particularly because IHM use is concomitant with
improved discharge processes, care coordination,
and nutrition bundles, which are all linked to better outcomes.3 Additional understanding of key
drivers of improvement can allow resources to
be targeted more effectively. It is unlikely a randomized trial will be performed because of the wide
acceptance of the benefits of IHM. Rather, further
research exploring the use of novel statistical techniques can assist in predicting which infants with a
single ventricle are most at risk for sudden death,
inform future interstage care, and define who may
benefit from remaining inpatient interstage.9,18 Use
of multilanguage, low literacy, affordable telehealth
and social media options for monitoring and communicating with families requires further investigation. The ultimate goal would be to lift the burden
of caregiver-driven data collection and assessments of deterioration onto the care coordination
team.23 In addition, there is limited research examining the psychological effects of IHM on caregivers.19 The interstage period is often perceived as a
highly stressful and anxious time. Future qualitative
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studies to address the interstage experience may
prove useful to address caregiver and family needs
and identify ways to improve IHM programs. 26
With caregiver education, nutritional management
and care c
 oordination being key elements in IHM,
there remain many opportunities for ongoing quality improvement and research. The development
of national quality improvement collaboratives
such as NPC-QIC, offer excellent forums for determining best practices and establishing benchmarks. Through collaboration and transparency
across centers, there is a continued effort to reach
100% survival in the population of infants with
SVHD.

SUMMARY
Infants with shunt-dependent SVHD pose unique
challenges during the interstage period for caregivers and the healthcare team related to potential sudden acute hemodynamic decompensation,
hypoxia, feeding difficulties, and somatic growth
failure. IHM is an innovative strategy developed
to augment conventional outpatient management
and to assist with early detection of physiologic
changes associated with morbidity and mortality
following successful S1P. There is overwhelming
evidence of improvement in single ventricle infant
survival and growth outcomes with IHM programs.
This surveillance strategy has become the standard of care for most pediatric cardiac programs
and continues to evolve using telehealth platforms
such as phone technology and tablet-based realtime video encounters in an effort to optimize data
collection and visual assessment of the infant at
home. The initial multisite examination of IHM effectiveness by NPC-QIC has laid the groundwork
for determining best practices and establishing
benchmarks for care. Together with improved care
coordination, discharge planning, and nutritional
management bundles, IHM is a key component
in optimizing outcomes in these high-risk infants.
Future collaborative research and quality improvement efforts should address the psychosocial
needs of caregivers to improve the IHM experience and further investigate additional key drivers impacting mortality and morbidity in the SVHD
population.
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